UMMS, RXi receive MLSC grant to develop RNAi therapeutics for ALS
UMMS, RXi receive MLSC grant to develop RNAi therapeutics for ALS
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that the company’s proposed research collaboration with the University of Massachusetts Medical School has been selected for Cooperative Research Matching Grant …
Read more on News-Medical-Net
Related Reading:
If you enjoyed this post, make sure you subscribe to my RSS feed!





